Serum manganese superoxide dismutase and thioredoxin are potential prognostic markers for hepatitis C virus-related hepatocellular carcinoma

AIM:To evaluate the clinical significance of oxidative stress markers in patients with hepatitis C virus(HCV)related hepatocellular carcinoma(HCC).METHODS:Sixty-four consecutive patients who were admitted to Kagoshima University Medical and Dental Hospital were enrolled in this retrospective study.A...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of gastroenterology : WJG Vol. 17; no. 44; pp. 4890 - 4898
Main Authors Tamai, Tsutomu, Uto, Hirofumi, Takami, Yoichiro, Oda, Kouhei, Saishoji, Akiko, Hashiguchi, Masashi, Kumagai, Kotaro, Kure, Takeshi, Mawatari, Seiichi, Moriuchi, Akihiro, Oketani, Makoto, Ido, Akio, Tsubouchi, Hirohito
Format Journal Article
LanguageEnglish
Published United States Baishideng Publishing Group Co., Limited 28.11.2011
Subjects
Online AccessGet full text

Cover

Loading…
Abstract AIM:To evaluate the clinical significance of oxidative stress markers in patients with hepatitis C virus(HCV)related hepatocellular carcinoma(HCC).METHODS:Sixty-four consecutive patients who were admitted to Kagoshima University Medical and Dental Hospital were enrolled in this retrospective study.All patients had chronic liver disease(CLD) due to infection with HCV.Thirty patients with HCV-related HCC,34 with HCV-related CLD without HCC(non-HCC),and 20 healthy volunteers(HVs) were enrolled.Possible associations between serum manganese superoxide dismutase(MnSOD) and thioredoxin(TRX) levels and clinical parameters or patient prognosis were analyzed over a mean follow-up period of 31.7 mo.RESULTS:The serum MnSOD levels were significantly higher in patients with HCV-related HCC than in patients without HCC(P = 0.03) or HVs(P 〈 0.001).Similarly,serum TRX levels were also significantly higher in patients with HCV-related HCC than in patients without HCC(P = 0.04) or HVs(P 〈 0.01).However,serum levels of MnSOD and TRX were not correlated in patients with HCC.Among patients with HCC,the overall survival rate(OSR) was lower in patients with MnSOD levels ≥ 110 ng/mL than in patients with levels 〈 110 ng/mL(P = 0.01),and the OSR tended to be lower in patients with TRX levels 〈 80 ng/mL(P = 0.05).In addition,patient prognosis with HCC was poorest with serum MnSOD levels ≥ 110 ng/mL and serum TRX levels 〈 80 ng/mL.Furthermore,a multivariate analysis using a Cox proportional hazard model and serum levels of five factors(MnSOD,prothrombin time,serum albumin,serum α-fetoprotein(AFP),and serum des-γ-carboxy prothrombin) revealed that MnSOD levels ≥ 110 ng/mL(risk ratio:4.12,95% confidential interval:1.22-13.88,P = 0.02) and AFP levels ≥ 40 ng/mL(risk ratio:6.75;95% confidential interval:1.70-26.85,P 〈 0.01) were independent risk factors associated with a poor patient prognosis.CONCLUSION:Serum MnSOD and TRX levels are potential clinical biomarkers that predict patient prognosis in HCV-related HCC.
AbstractList AIM: To evaluate the clinical significance of oxidative stress markers in patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC). METHODS: Sixty-four consecutive patients who were admitted to Kagoshima University Medical and Dental Hospital were enrolled in this retrospective study. All patients had chronic liver disease (CLD) due to infection with HCV. Thirty patients with HCV-related HCC, 34 with HCV-related CLD without HCC (non-HCC), and 20 healthy volunteers (HVs) were enrolled. Possible associations between serum manganese superoxide dismutase (MnSOD) and thioredoxin (TRX) levels and clinical parameters or patient prognosis were analyzed over a mean follow-up period of 31.7 mo. RESULTS: The serum MnSOD levels were significantly higher in patients with HCV-related HCC than in patients without HCC ( P = 0.03) or HVs ( P < 0.001). Similarly, serum TRX levels were also significantly higher in patients with HCV-related HCC than in patients without HCC ( P = 0.04) or HVs ( P < 0.01). However, serum levels of MnSOD and TRX were not correlated in patients with HCC. Among patients with HCC, the overall survival rate (OSR) was lower in patients with MnSOD levels ≥ 110 ng/mL than in patients with levels < 110 ng/mL ( P = 0.01), and the OSR tended to be lower in patients with TRX levels < 80 ng/mL ( P = 0.05). In addition, patient prognosis with HCC was poorest with serum MnSOD levels ≥ 110 ng/mL and serum TRX levels < 80 ng/mL. Furthermore, a multivariate analysis using a Cox proportional hazard model and serum levels of five factors (MnSOD, prothrombin time, serum albumin, serum α-fetoprotein (AFP), and serum des-γ-carboxy prothrombin) revealed that MnSOD levels ≥ 110 ng/mL (risk ratio: 4.12, 95% confidential interval: 1.22-13.88, P = 0.02) and AFP levels ≥ 40 ng/mL (risk ratio: 6.75; 95% confidential interval: 1.70-26.85, P < 0.01) were independent risk factors associated with a poor patient prognosis. CONCLUSION: Serum MnSOD and TRX levels are potential clinical biomarkers that predict patient prognosis in HCV-related HCC.
To evaluate the clinical significance of oxidative stress markers in patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC). Sixty-four consecutive patients who were admitted to Kagoshima University Medical and Dental Hospital were enrolled in this retrospective study. All patients had chronic liver disease (CLD) due to infection with HCV. Thirty patients with HCV-related HCC, 34 with HCV-related CLD without HCC (non-HCC), and 20 healthy volunteers (HVs) were enrolled. Possible associations between serum manganese superoxide dismutase (MnSOD) and thioredoxin (TRX) levels and clinical parameters or patient prognosis were analyzed over a mean follow-up period of 31.7 mo. The serum MnSOD levels were significantly higher in patients with HCV-related HCC than in patients without HCC (P = 0.03) or HVs (P < 0.001). Similarly, serum TRX levels were also significantly higher in patients with HCV-related HCC than in patients without HCC (P = 0.04) or HVs (P < 0.01). However, serum levels of MnSOD and TRX were not correlated in patients with HCC. Among patients with HCC, the overall survival rate (OSR) was lower in patients with MnSOD levels ≥ 110 ng/mL than in patients with levels < 110 ng/mL (P = 0.01), and the OSR tended to be lower in patients with TRX levels < 80 ng/mL (P = 0.05). In addition, patient prognosis with HCC was poorest with serum MnSOD levels ≥ 110 ng/mL and serum TRX levels < 80 ng/mL. Furthermore, a multivariate analysis using a Cox proportional hazard model and serum levels of five factors (MnSOD, prothrombin time, serum albumin, serum α-fetoprotein (AFP), and serum des-γ-carboxy prothrombin) revealed that MnSOD levels ≥ 110 ng/mL (risk ratio: 4.12, 95% confidential interval: 1.22-13.88, P = 0.02) and AFP levels ≥ 40 ng/mL (risk ratio: 6.75; 95% confidential interval: 1.70-26.85, P < 0.01) were independent risk factors associated with a poor patient prognosis. Serum MnSOD and TRX levels are potential clinical biomarkers that predict patient prognosis in HCV-related HCC.
AIM:To evaluate the clinical significance of oxidative stress markers in patients with hepatitis C virus(HCV)related hepatocellular carcinoma(HCC).METHODS:Sixty-four consecutive patients who were admitted to Kagoshima University Medical and Dental Hospital were enrolled in this retrospective study.All patients had chronic liver disease(CLD) due to infection with HCV.Thirty patients with HCV-related HCC,34 with HCV-related CLD without HCC(non-HCC),and 20 healthy volunteers(HVs) were enrolled.Possible associations between serum manganese superoxide dismutase(MnSOD) and thioredoxin(TRX) levels and clinical parameters or patient prognosis were analyzed over a mean follow-up period of 31.7 mo.RESULTS:The serum MnSOD levels were significantly higher in patients with HCV-related HCC than in patients without HCC(P = 0.03) or HVs(P 〈 0.001).Similarly,serum TRX levels were also significantly higher in patients with HCV-related HCC than in patients without HCC(P = 0.04) or HVs(P 〈 0.01).However,serum levels of MnSOD and TRX were not correlated in patients with HCC.Among patients with HCC,the overall survival rate(OSR) was lower in patients with MnSOD levels ≥ 110 ng/mL than in patients with levels 〈 110 ng/mL(P = 0.01),and the OSR tended to be lower in patients with TRX levels 〈 80 ng/mL(P = 0.05).In addition,patient prognosis with HCC was poorest with serum MnSOD levels ≥ 110 ng/mL and serum TRX levels 〈 80 ng/mL.Furthermore,a multivariate analysis using a Cox proportional hazard model and serum levels of five factors(MnSOD,prothrombin time,serum albumin,serum α-fetoprotein(AFP),and serum des-γ-carboxy prothrombin) revealed that MnSOD levels ≥ 110 ng/mL(risk ratio:4.12,95% confidential interval:1.22-13.88,P = 0.02) and AFP levels ≥ 40 ng/mL(risk ratio:6.75;95% confidential interval:1.70-26.85,P 〈 0.01) were independent risk factors associated with a poor patient prognosis.CONCLUSION:Serum MnSOD and TRX levels are potential clinical biomarkers that predict patient prognosis in HCV-related HCC.
Author Tsutomu Tamai Hirofumi Uto Yoichiro Takami Kouhei Oda Akiko Saishoji Masashi Hashiguchi Kotaro Kumagai Takeshi Kure Seiichi Mawatari Akihiro Moriuchi Makoto Oketani Akio Ido Hirohito Tsubouchi
AuthorAffiliation Department of Digestive and Lifestyle Related Diseases, Human and Environmental Sciences, Health Research, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan
Author_xml – sequence: 1
  givenname: Tsutomu
  surname: Tamai
  fullname: Tamai, Tsutomu
  organization: Department of Digestive and Lifestyle Related Diseases, Human and Environmental Sciences, Health Research, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan
– sequence: 2
  givenname: Hirofumi
  surname: Uto
  fullname: Uto, Hirofumi
– sequence: 3
  givenname: Yoichiro
  surname: Takami
  fullname: Takami, Yoichiro
– sequence: 4
  givenname: Kouhei
  surname: Oda
  fullname: Oda, Kouhei
– sequence: 5
  givenname: Akiko
  surname: Saishoji
  fullname: Saishoji, Akiko
– sequence: 6
  givenname: Masashi
  surname: Hashiguchi
  fullname: Hashiguchi, Masashi
– sequence: 7
  givenname: Kotaro
  surname: Kumagai
  fullname: Kumagai, Kotaro
– sequence: 8
  givenname: Takeshi
  surname: Kure
  fullname: Kure, Takeshi
– sequence: 9
  givenname: Seiichi
  surname: Mawatari
  fullname: Mawatari, Seiichi
– sequence: 10
  givenname: Akihiro
  surname: Moriuchi
  fullname: Moriuchi, Akihiro
– sequence: 11
  givenname: Makoto
  surname: Oketani
  fullname: Oketani, Makoto
– sequence: 12
  givenname: Akio
  surname: Ido
  fullname: Ido, Akio
– sequence: 13
  givenname: Hirohito
  surname: Tsubouchi
  fullname: Tsubouchi, Hirohito
BackLink https://www.ncbi.nlm.nih.gov/pubmed/22171130$$D View this record in MEDLINE/PubMed
BookMark eNpVkctu1DAUhi1URKeFPStkHiCDb4mTDRIaQYtUiQWwts7YJxmXxA52MsA78NC4mjKClSX_l3Ps74pchBiQkJecbaVW7Zsf98P2yPXWK7VVbceekI0QvKtEq9gF2XDGdNVJoS_JVc73jAkpa_GMXBaT5lyyDfn9GdM60QnCAAEz0rzOmOJP75A6n6d1gXIJwdHl4GNCV6RAISGd44Jh8TDSOcUhxLx4W3rSN0yZ9jHRA86w-MVnuqNHn9ZcJRxhQXdSosVxXEdI1EKyPsQJnpOnPYwZXzye1-Trh_dfdrfV3aebj7t3d5VVrV6qBlqmHTRW7kWj9g60tHxva9a10DZSKI5a2QbqGljvnGyZFH3NWcd4LcsXyGvy9tQ7r_sJnS3vSDCaOfmy_y8TwZv_leAPZohHU9J1GVAK2KnApphzwv6c5cw8kDGFjClkTCFjHsiUyKt_Z54Df1EUw-vHzkMMw3cfhrNHMc3rRin5B8ZQnV0
CitedBy_id crossref_primary_10_2169_internalmedicine_51_6021
crossref_primary_10_2174_1573394718666220829122410
crossref_primary_10_3390_antiox12051078
crossref_primary_10_1089_ars_2013_5295
crossref_primary_10_1016_j_humpath_2017_12_032
crossref_primary_10_3109_1354750X_2012_685952
crossref_primary_10_1158_0008_5472_CAN_16_0987
crossref_primary_10_1155_2013_380797
crossref_primary_10_1021_acs_jpcc_5b03681
crossref_primary_10_1016_j_bbacli_2014_09_006
crossref_primary_10_1155_2014_541230
crossref_primary_10_2957_kanzo_56_313
crossref_primary_10_1007_s10803_020_04677_z
crossref_primary_10_1007_s11356_017_8595_3
crossref_primary_10_18632_oncotarget_3314
crossref_primary_10_1016_j_bcp_2014_12_001
crossref_primary_10_1080_14737140_2022_2139681
crossref_primary_10_1080_1120009X_2023_2203607
crossref_primary_10_3390_v5020439
crossref_primary_10_18632_oncotarget_13904
crossref_primary_10_3390_ijms20215266
crossref_primary_10_1177_1724600819841619
crossref_primary_10_1517_17530059_2013_795146
crossref_primary_10_5812_hepatmon_144896
crossref_primary_10_1016_j_rasd_2015_08_001
ContentType Journal Article
Copyright 2011 Baishideng Publishing Group Co., Limited. All rights reserved. 2011
Copyright_xml – notice: 2011 Baishideng Publishing Group Co., Limited. All rights reserved. 2011
DBID 2RA
92L
CQIGP
W91
~WA
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
5PM
DOI 10.3748/wjg.v17.i44.4890
DatabaseName 维普_期刊
中文科技期刊数据库-CALIS站点
中文科技期刊数据库-7.0平台
中文科技期刊数据库-医药卫生
中文科技期刊数据库- 镜像站点
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
DatabaseTitleList
MEDLINE

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
DocumentTitleAlternate Serum manganese superoxide dismutase and thioredoxin are potential prognostic markers for hepatitis C virus-related hepatocellular carcinoma
EISSN 2219-2840
EndPage 4898
ExternalDocumentID 10_3748_wjg_v17_i44_4890
22171130
40715644
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
123
29R
2B.
2C~
2RA
2WC
36B
53G
5VR
8WL
92F
92I
92L
93N
93R
AAKDD
ACGFO
AENEX
AFUIB
ALMA_UNASSIGNED_HOLDINGS
CCEZO
CHBEP
CIEJG
CQIGP
CS3
CW9
DIK
DU5
E3Z
EBS
EJD
EMB
F5P
FA0
FRP
GX1
HYE
M~E
OK1
P2P
RNS
RPM
SV3
TCJ
TGQ
TR2
W91
WFFXF
XSB
~WA
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
5PM
ID FETCH-LOGICAL-c487t-6a807da6c3b264bda73c1bc5098a863241e74c6a55a0fdd38032f510901532333
IEDL.DBID RPM
ISSN 1007-9327
IngestDate Tue Sep 17 21:23:56 EDT 2024
Fri Aug 23 04:00:05 EDT 2024
Thu May 23 23:17:06 EDT 2024
Wed Feb 14 10:47:02 EST 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 44
Keywords Oxidative stress
Hepatocellular carcinoma
Hepatitis C virus
Thioredoxin
Manganese superoxide dismutase
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c487t-6a807da6c3b264bda73c1bc5098a863241e74c6a55a0fdd38032f510901532333
Notes 14-1219/R
AIM:To evaluate the clinical significance of oxidative stress markers in patients with hepatitis C virus(HCV)related hepatocellular carcinoma(HCC).METHODS:Sixty-four consecutive patients who were admitted to Kagoshima University Medical and Dental Hospital were enrolled in this retrospective study.All patients had chronic liver disease(CLD) due to infection with HCV.Thirty patients with HCV-related HCC,34 with HCV-related CLD without HCC(non-HCC),and 20 healthy volunteers(HVs) were enrolled.Possible associations between serum manganese superoxide dismutase(MnSOD) and thioredoxin(TRX) levels and clinical parameters or patient prognosis were analyzed over a mean follow-up period of 31.7 mo.RESULTS:The serum MnSOD levels were significantly higher in patients with HCV-related HCC than in patients without HCC(P = 0.03) or HVs(P 〈 0.001).Similarly,serum TRX levels were also significantly higher in patients with HCV-related HCC than in patients without HCC(P = 0.04) or HVs(P 〈 0.01).However,serum levels of MnSOD and TRX were not correlated in patients with HCC.Among patients with HCC,the overall survival rate(OSR) was lower in patients with MnSOD levels ≥ 110 ng/mL than in patients with levels 〈 110 ng/mL(P = 0.01),and the OSR tended to be lower in patients with TRX levels 〈 80 ng/mL(P = 0.05).In addition,patient prognosis with HCC was poorest with serum MnSOD levels ≥ 110 ng/mL and serum TRX levels 〈 80 ng/mL.Furthermore,a multivariate analysis using a Cox proportional hazard model and serum levels of five factors(MnSOD,prothrombin time,serum albumin,serum α-fetoprotein(AFP),and serum des-γ-carboxy prothrombin) revealed that MnSOD levels ≥ 110 ng/mL(risk ratio:4.12,95% confidential interval:1.22-13.88,P = 0.02) and AFP levels ≥ 40 ng/mL(risk ratio:6.75;95% confidential interval:1.70-26.85,P 〈 0.01) were independent risk factors associated with a poor patient prognosis.CONCLUSION:Serum MnSOD and TRX levels are potential clinical biomarkers that predict patient prognosis in HCV-related HCC.
Oxidative stress Manganese superoxide dismutase Thioredoxin Hepatitis C virus Hepatocellular carcinoma
Telephone: +81-99-2755326 Fax: +81-99-2643504
Correspondence to: Hirofumi Uto, MD, PhD, Department of Digestive and Lifestyle Related Diseases, Human and Environmental Sciences, Health Research, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan. hirouto@m2.kufm.kagoshima-u.ac.jp
Author contributions: Tamai T and Takami Y performed the majority of experiments; Uto H and Tsubouchi H were involved in editing the manuscript; Uto H, Oda K, Saishoji A, Hashiguchi M, Kumagai K, Kure T, Mawatari S, Moriuchi A, Oketani M and Ido A coordinated the collection of and provided all the human material for this work; Tamai T and Uto H designed the study and wrote the manuscript.
OpenAccessLink https://doi.org/10.3748/wjg.v17.i44.4890
PMID 22171130
PageCount 9
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_3235632
crossref_primary_10_3748_wjg_v17_i44_4890
pubmed_primary_22171130
chongqing_primary_40715644
PublicationCentury 2000
PublicationDate 2011-11-28
PublicationDateYYYYMMDD 2011-11-28
PublicationDate_xml – month: 11
  year: 2011
  text: 2011-11-28
  day: 28
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle World journal of gastroenterology : WJG
PublicationTitleAlternate World Journal of Gastroenterology
PublicationYear 2011
Publisher Baishideng Publishing Group Co., Limited
Publisher_xml – name: Baishideng Publishing Group Co., Limited
References 10638941 - Clin Biochem. 1999 Nov;32(8):595-603
7248954 - Cancer Res. 1981 Jul;41(7):2962-6
21143527 - APMIS. 2011 Jan;119(1):57-65
11059866 - J Hepatol. 2000 Oct;33(4):616-22
9564042 - EMBO J. 1998 May 1;17(9):2596-606
7951854 - J Gastroenterol. 1994 Aug;29(4):443-9
17617122 - Liver Int. 2007 Aug;27(6):791-7
17393466 - Hepatology. 2007 Apr;45(4):948-56
20012107 - J Gastroenterol. 2010 Apr;45(4):459-67
1682406 - J Lab Clin Med. 1991 Nov;118(5):476-83
18069771 - World J Gastroenterol. 2007 Dec 14;13(46):6264-8
20236361 - Hepatol Res. 2010 Apr;40(4):438-45
11131450 - J Hepatol. 2000 Dec;33(6):893-901
11147597 - Cancer. 2000 Dec 1;89(11):2266-73
21374666 - Hepatology. 2011 Mar;53(3):1020-2
11007950 - Biochem Pharmacol. 2000 Oct 15;60(8):1121-8
15508082 - Gastroenterology. 2004 Nov;127(5 Suppl 1):S17-26
12480557 - J Hepatol. 2003 Jan;38(1):32-8
16458876 - Clin Chim Acta. 2006 May;367(1-2):156-61
19566940 - J Exp Clin Cancer Res. 2009;28:93
9329312 - BMJ. 1997 Aug 30;315(7107):540-3
11115602 - Int J Mol Med. 2001 Jan;7(1):13-9
10733537 - Hepatology. 2000 Apr;31(4):840-5
15977232 - J Med Virol. 2005 Aug;76(4):489-97
11226300 - Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2688-93
18636507 - IUBMB Life. 2008 Oct;60(10):656-60
17896802 - J Rheumatol. 2007 Oct;34(10):2035-43
21296855 - CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
17336594 - Clin Gastroenterol Hepatol. 2007 May;5(5):630-5
2978223 - J Mol Cell Immunol. 1985;2(1):17-26
11853397 - Virology. 2002 Feb 1;293(1):31-43
16407224 - J Biol Chem. 2006 Mar 17;281(11):7384-91
2659865 - Jpn J Surg. 1989 Jan;19(1):98-129
14670077 - Biochem J. 2004 Mar 15;378(Pt 3):919-28
2313102 - J Immunol Methods. 1990 Mar 9;127(2):249-54
11832451 - Gastroenterology. 2002 Feb;122(2):366-75
6170301 - Br J Cancer. 1981 Oct;44(4):502-5
15629516 - J Hepatol. 2005 Jan;42(1):117-23
7382552 - Mayo Clin Proc. 1980 Jul;55(7):434-8
15565571 - Hepatology. 2004 Dec;40(6):1396-405
11758836 - Life Sci. 2001 Nov 9;69(25-26):3113-9
21710498 - Int J Cancer. 2011 Sep 1;129(5):1254-64
20206073 - J Cardiol. 2010 Mar;55(2):205-10
11812920 - Toxicol Sci. 2002 Feb;65(2):166-76
12498974 - Free Radic Biol Med. 2003 Jan 1;34(1):1-10
15589129 - Hepatol Res. 2004 Dec;30(4):214-220
15818395 - Cell Death Differ. 2005 Aug;12 Suppl 1:991-8
9731568 - Hepatology. 1998 Sep;28(3):751-5
2003603 - Am J Physiol. 1991 Mar;260(3 Pt 1):G355-62
References_xml
SSID ssj0023352
Score 2.203022
Snippet AIM:To evaluate the clinical significance of oxidative stress markers in patients with hepatitis C virus(HCV)related hepatocellular...
To evaluate the clinical significance of oxidative stress markers in patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC). Sixty-four...
AIM: To evaluate the clinical significance of oxidative stress markers in patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC)....
SourceID pubmedcentral
crossref
pubmed
chongqing
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 4890
SubjectTerms Aged
alpha-Fetoproteins - metabolism
Animals
Biomarkers - blood
Biomarkers, Tumor - blood
Brief
Carcinoma, Hepatocellular - blood
Carcinoma, Hepatocellular - enzymology
Carcinoma, Hepatocellular - virology
Diagnosis, Differential
Female
Hepacivirus - pathogenicity
Hepatitis C - blood
Hepatitis C - enzymology
Hepatitis C - virology
Humans
Liver Neoplasms - blood
Liver Neoplasms - enzymology
Liver Neoplasms - virology
Male
Middle Aged
MnSOD
Oxidative Stress
Prognosis
Protein Precursors - blood
Prothrombin
Retrospective Studies
Superoxide Dismutase - blood
Survival Rate
Thioredoxins - blood
丙型肝炎病毒
凝血酶原时间
硫氧还蛋白
肝癌
血清白蛋白
锰超氧化物歧化酶
预后
Title Serum manganese superoxide dismutase and thioredoxin are potential prognostic markers for hepatitis C virus-related hepatocellular carcinoma
URI http://lib.cqvip.com/qk/84123X/201144/40715644.html
https://www.ncbi.nlm.nih.gov/pubmed/22171130
https://pubmed.ncbi.nlm.nih.gov/PMC3235632
Volume 17
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3BTuMwELWAC3tBi2CXsoB84MIhaVLHsXtEFQitBOIAErfIsZ3WC3FKmwIfwUczkzQRve7ZiRN5xp737DdjQs7zmFkDVCMoCq4DgNQ2yDWHiQdYQSYcN_Uxwfn2Lr15TP4-8actwrtcmEa0r3MX-pcy9G7WaCvnpR52OrHh_e2EjRhP2Wi4TbbBQTuKvmZZmETUHHFGIoAPivZsEqusDN__TcO3WIQuScJEjvEWuBFA8jhGDfQuLDd--goBYyNE9XFpUzP5LQhd_yR7a_RIL9u_3Cdb1h-QT5jvq5KWyk8V3idJlyus_v3hjKXGLUtUXVuqvKH1zFVYIPTDeaoWls6rGsVC0CPKtHyFNZuhn8UzYEIKaJbOLAqua7ekE_rmFqtl0OS-WNO2VLjtjzpWqvFKIl-V6pA8Xl89TG6C9SULgQauUgepkpEwKtUsB2yUGyWYjsFc0VgqibXcYysSnSrOVVQYw2TERgVHOSeslTDY7BfZ8ZW3R4QqA-hJWYAYwLusVjLn0khmJXCaQhZiQI77Mc7mbTGNDAklB1A2IBfdoPdtQFDQbhnYDci8yMBuGdptQH63xuif7Mw4IGLDTP0DWEV7swWcq6mmvXam4_9-8w_5EY9l0u7LnJCderGyp4BU6vys8cwv-1rsNg
link.rule.ids 230,315,730,783,787,888,27936,27937,53804,53806
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV07b9swECaSdEiWokUfcfri0CWDZEkURWYsjAZuGwcZEiCbQJGUzSSiXFtO8yP6o3snWUK9BtBGihJ4fHwf-d0dIV-LmFkDVCMoS64DgNQ2KDSHiQdYQaYcD_XRwXl2mU1v0p-3_HaP8N4XphXt68KF_qEKvVu02splpce9Tmx8NZuwhPGMJeN98gLma5T2JH3Ls9CNqL3kjEQAnxTd7STGWRn_uZuHj7EIXZqGqTzDPHAJgPI4RhX0ISw4fv4btoydTWrYmXZVk_9tQ-evyMstfqTfuv98Tfasf0P-wozfVLRSfq4woyRdbzD-95Mzlhq3rlB3banyhjYLV2OI0CfnqVpZuqwblAtBiyjU8jVGbYZ2VveACingWbqwKLlu3JpO6KNbbdZB6_1iTVdS48E_KlmpxqREvq7UW3Jz_v16Mg22aRYCDWylCTIlI2FUplkB6KgwSjAdg8GiM6kkRnOPrUh1pjhXUWkMdDhLSo6CTlgtobPZO3Lga2-PCVUG8JOyADKAeVmtZMGlkcxKYDWlLMWInAx9nC-7cBo5UkoOsGxETvtOH8qAoqDdcrAb0HmRg91ytNuIvO-MMdTszTgiYsdMQwWMo71bAsOrjae9HU4nz37zCzmcXs8u8osfl78-kKP22BmeRH4kB81qYz8BbmmKz-0o_QeMI--E
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV07b9swECaaFEi6FC3apHZfHLp00JOiyIyFWyN9JMjQANkEiqRsphXl2HKSH9Ef3TvJFuI1gDZSlMAjed9Hfrwj5FOZMGuAagRVxXUAkNoGpeYw8QAryIzjpj5ecD47z08vsx9X_OpBqq9OtK9LF_q_dejdvNNWLmodbXVi0cXZhKWM5yyNFqaK9shTmLNxviXqG66FV4m6g85YBPBZ0Z9QYqyV6O56Ft4mInRZFmbyBHPBpQDMkwSV0Iew6PjZDbiNHUc1eKdd5eQDVzR9QZ5vMCT90v_rS_LE-lfkH8z6dU1r5WcKs0rS1RpjgN87Y6lxqxq115Yqb2g7dw2GCb13nqqlpYumRckQtIhiLd9g5GZoZ_kHkCEFTEvnFmXXrVvRCb11y_Uq6G7AWNOXNLj5j2pWqjExkW9q9ZpcTr_9npwGm1QLgQbG0ga5krEwKtesBIRUGiWYTsBo8YlUEiO6J1ZkOlecq7gyBjqcpRVHUSesmNDZ7Ijs-8bbN4QqAxhKWQAawL6sVrLk0khmJTCbSlZiRMZDHxeLPqRGgbSSAzQbkc_bTh_KgKag3QqwG1B6UYDdCrTbiBz3xhhqbs04ImLHTEMFjKW9WwJDrIupvRlS40e_-ZEcXHydFr--n_98S551O8_wpPId2W-Xa_seoEtbfugG6X_z3vCX
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Serum+manganese+superoxide+dismutase+and+thioredoxin+are+potential+prognostic+markers+for+hepatitis+C+virus-related+hepatocellular+carcinoma&rft.jtitle=World+journal+of+gastroenterology+%3A+WJG&rft.au=Tamai%2C+Tsutomu&rft.date=2011-11-28&rft.issn=1007-9327&rft.volume=17&rft.issue=44&rft.spage=4890&rft_id=info:doi/10.3748%2Fwjg.v17.i44.4890&rft.externalDBID=n%2Fa&rft.externalDocID=10_3748_wjg_v17_i44_4890
thumbnail_s http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F84123X%2F84123X.jpg